[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557774":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":61,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":32,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":32,"enrollmentInfo":76,"targetDuration":32,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":52,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Nagoya City University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Gefapixiant arm","EXPERIMENTAL","Participants will take 45mg of gefapixiant twice a day for 12 weeks.",[13],"Drug: Gefapixant Citrate",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Gefapixant Citrate","An additional treatment of gefapixiant will be performed for 12 weeks.",[9],[21],"LYFNUA Tablets",[23],{"name":24,"affiliation":25,"role":26},"Yoshihiro Kanemitsu","Nagoya City University Graduate School of Medical Sciences and Medical School","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Yoshihiro Kanemitsu, MD, PhD","CONTACT","+81-52-853-8216",null,"kaney32@med.nagoya-cu.ac.jp",[35,50],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"NOT_YET_RECRUITING","Nagoya","Aichi-ken","467-8601","Japan","JP",{"type":43,"coordinates":44},"Point",[45,46],136.90641,35.18147,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},{"facility":51,"status":52,"city":37,"state":38,"zip":53,"country":40,"countryCode":41,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"Nagoya City University Hospital","RECRUITING","4678601",{"type":43,"coordinates":55},[45,46],{"lat":46,"lon":45},[58],{"name":59,"role":30,"phone":60,"phoneExt":32,"email":33},"Kanemitsu Yoshihiro, MD, PhD","+81-52-85308216",{"type":26,"investigatorFullName":24,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Lecturer",[64],{"name":65,"class":66},"Merck Sharp & Dohme LLC","INDUSTRY","100557774","the-real-world-treatment-satisfaction-by-gefapixiant-in-rcc-100557774",false,"NCT06542484","The Real-world Treatment Satisfaction by Gefapixiant in RCC","The Real-world Treatment Satisfaction by Gefapixiant in Patients with Refractory Chronic Cough in Terms of Cough Improvement and Taste Disturbance. (The RESTORE Study)","Inclusion Criteria:\n\n1. Adult patients with RCC and UCC (8 weeks or more).\n2. Cough is refractory to intensive specific treatments for causes of chronic cough.\n3. Never smokers and ex-smokers with having smoking history of ≤20 pack-years.\n\nExclusion Criteria:\n\n1. Patients with lung cancer, interstitial lung diseases, bronchiectasis, or respiratory infection such as tuberculosis and acute pneumonia.\n2. Current smoker, ex-smokers with having smoking history of \\>20 pack-years, or those who quit smoking within six months prior to receiving gefapixant.\n3. Those who are pregnant.","ALL","18 Years",{"count":77,"type":78},63,"ESTIMATED","INTERVENTIONAL",[81],"NA","Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste disturbance has occurred, the impact of taste disturbance on cough-specific QoL remains to be unclear. Therefore, the investigator would like to evaluate factors related to treatment satisfaction by gefapixant in RCC patients. the investigator hypothesize that taste disturbance will be associated with the improvement of cough specific QoL and treatment satisfaction in RCC patients.",[84],"Chronic Cough",[84,86],"gefapixiant","2025-01-26",{"date":89,"type":90},"2025-01-29","ACTUAL",{"date":92,"type":90},"2024-12-04",{"date":94,"type":78},"2026-06-30",{"name":5,"class":6},2]